Radionetics Oncology closes $52.2M Series A funding led by Frazier Life Sciences, 5AM Ventures and DCVC Bio with additional support from Crinetics Pharmaceuticals, and GordonMD Global Investments.

Radionetics plans to use the proceeds to advance its pipeline of potent, small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) for the treatment of a broad range of cancers.